Recent Updates — CLLS

Cellectis S.A. announced a strategic transformation to become an in vivo gene editing company, focusing on two lead programs: .HEAL-101 for severe hypertriglyceridemia and .HEAL-201 for severe hypercholesterolemia. The board approved exiting the development of lasme-cel and eti-cel due to a changing competitive landscape while continuing existing cell therapy partnerships with AstraZeneca, Allogene, Servier, and Iovance. This operational realignment aims to extend the company's cash runway into H2 2028. Preliminary Phase 1 data for .HEAL-101 is planned for H2 2027, and for .HEAL-201 in H1 2028. Cellectis operates in the biotechnology industry, developing genetic medicines using genome engineering platforms.

Cellectis reported financial results for the second quarter ended June 30, 2026. The company held $169 million in cash and equivalents, providing a runway into Q4 2027. Revenues decreased to $14.5 million from $30.2 million in the prior year period due to lower activity under the AstraZeneca collaboration agreement. R&D expenses rose to $52.2 million as clinical development costs for lasme-cel and eti-cel increased. The net loss attributable to shareholders was $39.6 million, or $0.39 per share, compared to a $41.9 million loss in the same period last year. Clinically, Cellectis received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for lasme-cel in relapsed/refractory B-cell acute lymphoblastic leukemia and presented full Phase 1 data from the BALLI-01 trial at EHA 2026 showing a 100% overall response rate in the target population. The company also presented translational data for eti-cel in non-Hodgkin lymphoma. Cellectis is a clinical-stage biotechnology company developing gene-edited cell and gene therapies.